The global tumor ablation market was valued at USD 508.2 million in 2020. Increase in prevalence of cancer, shift towards minimally invasive surgeries along with rapid technological advancements in ablation devices are key factors driving the global tumor ablation market.
The need for tumor ablation has increased dramatically due to increase in incidence of cancer across the globe. There are a variety of ablation methods that may be used to treat a tumor percutaneously. Radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation are the most often employed modalities. Moreover, increase in preference for minimally invasive surgeries owing to benefits offered reduced turnaround time, patient comfort, and speedy recovery will further boost growth of the market in the next few years.
The global tumor ablation market has been segmented based on technology, treatment type, application, and region. Based on technology, the global tumor ablation market is categorized into radiofrequency ablation, microwave ablation, cryoablation, irreversible ablation, and other. Radiofrequency ablation segment held the largest share of global market in 2020. On the basis of treatment type, the global tumor ablation market is segmented into surgical, laparoscopic and percutaneous ablation. Application-wise, the global tumor ablation market is categorized into lung cancer, kidney cancer, liver cancer, bone metastasis, and others. Geographically, North America dominated the global tumor ablation market in 2020, however, Asia Pacific is expected to be the fastest growing region by 2028.
Key players operating in the global tumor ablation market include Medtronic plc, AngioDynamics, Inc., HealthTronics, Inc., Galil Medical, Inc., SonaCare Medical LLC, Mermaid Medical, NeuWave Medical, Inc., Theraction, Ethicon Inc., and Boston Scientific Corporation among others.
Tumor Ablation Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 508.2 million|
|Growth Rate||CAGR of 13.1% during 2021-2028|
|Segment Covered||Technology, Treatment Type, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Key Players Profiled||Medtronic plc, AngioDynamics, Inc., HealthTronics, Inc., Galil Medical, Inc., SonaCare Medical LLC, Mermaid Medical, NeuWave Medical, Inc., Theraction, Ethicon Inc., and Boston Scientific Corporation among others.|
Key Segments of the Global Tumor Ablation Market
Technology Overview, 2018-2028 (USD Million)
- Radiofrequency Ablation
- Microwave Ablation
- Irreversible Ablation
Treatment Type Overview, 2018-2028 (USD Million)
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
Application Overview, 2018-2028 (USD Million)
- Liver Cancer
- Kidney Cancer
- Lung Cancer
- Bone Metastasis
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Reasons for the study
- Increase in prevalence of cancer worldwide
- Growing preference for minimally invasive procedures
- Rapid technological advancements in ablation devices
What does the report include?
- The study on the global tumor ablation market includes qualitative insights such as drivers, restraints, challenges and opportunities
- Additionally, the market has been evaluated using the Porter’s Five Forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of type, material, origin, and region.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players operating in the market
Who should buy this report?
- The report on the global tumor ablation market is suitable for all the players across the value chain including raw material suppliers, hospitals & clinics, medical device manufacturers, healthcare organizations, distributors, suppliers and technology geeks
- Venture capitalists and investors looking for more information on the future outlook of the global tumor ablation market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global tumor ablation market
Frequently Asked Questions (FAQ) :
Thermal ablation has become an integral part of oncology, especially in the field of interventional oncology. Percutaneous tumor ablation has been shown to be a safe and effective treatment that provides long-term tumor control and enhanced patient survival. Moreover, continuous technical developments in diagnostic imaging and guidance tools, as well as the creation of technologies that allow for the optimization of ablation parameters and the capacity to perform margin evaluation has increased the efficacy of ablation. Furthermore, increasing shift to minimally invasive techniques will propel growth of the market in the future. These procedures are performed through smaller incisions rather than large opening leading to lower blood loss and quick recovery of patients. Benefits associated with these less-invasive treatments such as speedy recovery, reduced hospitalization period, curtailed risk of infections and lower operative pain will positively influence market growth over the coming years.
The global tumor ablation market has been segmented based on technology, treatment type, application, and region. Based on technology, the global tumor ablation market is categorized into radiofrequency ablation, microwave ablation, cryoablation, irreversible ablation, and other. Microwave ablation segment held substantial share of the global market in 2020. Microwave ablation produces direct volume heating of tissue by using dielectric hysteresis. Microwaves may pass through a variety of tissue types, even those with high impedance, such as the lungs or bones, with decreased vulnerability to heat-sink effects along vessels. Microwaves are well suited to the employment of numerous applicators, demonstrating not only the synergy found with other energies, but also the possibility for electromagnetic field phasing. As a consequence, it may be possible to generate bigger, more customizable ablation zones in less time. All these factors are anticipated to drive the growth of the market in the forthcoming years.
Based on treatment type, the global the global tumor ablation market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation. Surgical ablation segment grabbed majority of the market share in 2020. Application-wise, the global tumor ablation market is segregated into liver cancer, kidney cancer, lung cancer, bone metastasis and others. Kidney cancer is expected to grow at a significant rate during the forecast period. Kidney cancers can be effectively treated with radiofrequency and microwave ablation techniques. Patients with solitary kidneys, small tumors, and a poor post-surgical recovery rate are good prospects for kidney tumor ablation.
The global tumor ablation market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global tumor ablation market in 2020, however Asia Pacific is expected to grow at a rapid pace through 2028.
Early adoption of tumor ablation technologies, ongoing technical breakthroughs in the field of tumor ablation catheters, coupled with the growing public awareness related to the benefits of tumor ablation are major factors anticipated to drive the market in the U.S. and Canada. Furthermore, presence of large elderly patient population, increase in incidence of cancer coupled with strong foothold of key industry players are other major factors likely to boost the growth of the market in North America.
However, Asia Pacific is expected to grow at a rapid pace over the next few years. There is a strong growth potential in the emerging economies such as India, and China. The rapidly rising geriatric population in countries such as India China, and Japan, increase in prevalence of cancer along with high unmet clinical needs provide large market for tumor ablation. According to WHO and Globocan, there were 108,503 new cases of kidney cancer in Eastern Asia in 2020. Furthermore, increased awareness of diagnostic procedures and treatment options for certain cancers has created enormous opportunities for market growth.